Haemodialysis and Peritoneal Dialysis Market Report and Forecast 2024-2032

According to the report, the global haemodialysis and peritoneal dialysis market is projected to grow at a CAGR of 5.6% between 2024 and 2032 reaching a value of approximate USD 130.76 billion by 2032. Aided by the rising prevalence of chronic kidney diseases (CKD) and increased awareness about renal replacement therapies, the market is expected to grow significantly by 2032.

Haemodialysis and peritoneal dialysis are two primary methods of dialysis treatment for kidney failure patients. Haemodialysis involves the purification of the patient's blood using a machine outside the body, commonly referred to as a dialyser. In contrast, peritoneal dialysis utilises the patient's peritoneal membrane in the abdomen to filter toxins from the blood. Both methods aim to remove waste products and excess fluids, thereby aiding in the patient's overall well-being.

The soaring incidence of diabetes, hypertension, and other lifestyle diseases has significantly contributed to the increase in chronic kidney diseases worldwide. As kidneys lose their filtering capacity, the need for renal replacement therapies, like haemodialysis and peritoneal dialysis, has witnessed an upward trajectory. Consequently, the growing number of CKD patients globally has been instrumental in driving the haemodialysis and peritoneal dialysis market growth.

Furthermore, technological advancements in the field of dialysis have bolstered the market's growth. The introduction of wearable and portable dialysis devices, along with innovative solutions for home-based dialysis treatments, has expanded the scope and accessibility of dialysis for many patients. These advancements not only provide flexibility and convenience but also offer improved patient outcomes and quality of life.

The pharmaceutical industry's role in complementing dialysis treatments cannot be understated. The development of new drugs and solutions designed specifically for dialysis patients has amplified the efficiency and safety of the treatment. Innovations in the formulation of dialysates, anticoagulants, and other necessary medications have further strengthened the synergies between pharmaceuticals and dialysis, propelling the overall haemodialysis and peritoneal dialysis market demand.

Moreover, the rise in healthcare infrastructure, especially in emerging economies, has augmented the accessibility of dialysis treatments. The expansion of specialised nephrology clinics and dialysis centres has made it easier for patients to avail timely and effective treatments. Government initiatives and policies promoting awareness about CKD and subsidising dialysis treatments have further posed a positive impact on the haemodialysis and peritoneal dialysis market outlook.

Market Segmentation

The market can be divided based on type, product, end use, and region.

Market Breakup by Type

• Haemodialysis
• Conventional Haemodialysis
• Nocturnal Haemodialysis
• Peritoneal Dialysis
• Continuous Ambulatory Peritoneal Dialysis (CAPD)
• Automated Peritoneal Dialysis (APD)

Market Breakup by Product

• Device
• Machine
• Dialyzer
• Water Treatment System
• Others
• Consumables
• Bloodline
• Concentrates
• Catheters
• Others

Market Breakup by End Use

• Home-Based Dialysis
• Hospital-Based Dialysis

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Competitive Landscape

The report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the leading companies operating in the global haemodialysis and peritoneal dialysis market. Some of the major players explored in the report are as follows:

• NxStage Medical, Inc.
• NIPRO Medical Corporation
• B. Braun Melsungen AG
• Baxter International Inc.
• Diaverum AB
• Nikkiso Co., Ltd.
• Asahi Kasei Co., Ltd.
• DaVita Inc.
• Others